Efficacy and safety of enfortumab and pembrolizumab in urothelial carcinoma

Until now, no treatment has shown superior efficacy to platinum-based chemotherapy in improving overall survival in patients with treatment-naive locally advanced or metastatic urothelial carcinoma. In this phase 3 clinical trial, investigators compared the efficacy and safety of enfortumab and pembrolizumab to platinum-based chemotherapy in 886 patients with previously untreated locally advanced or metastatic urothelial carcinoma. Progression-free survival and overall survival were longer in the enfortumab - pembrolizumab arm than in the chemotherapy arm. The median number of treatment cycles was 12 in the enfortumab - pembrolizumab arm, and 6 in the chemotherapy arm.